Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Other Intangible Assets (Tables)

v3.5.0.2
Note 4 - Other Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2016
Notes Tables  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
           
As of June 30, 2016
 
   
Life
   
Carrying
 
   
(Years)
   
Amount
 
Diagnostic assets:
 
 
 
 
 
 
 
 
Asuragen acquisition:
               
Thyroid
    9     $ 8,519  
Pancreas
    7       2,882  
Biobank
    4       1,575  
RedPath acquisition:
               
Pancreas test
    7       16,141  
Barrett's test
    9       18,351  
Total
          $ 47,468  
Diagnostic lab:
 
 
 
 
 
 
 
 
CLIA Lab
    2.3     $ 609  
                 
Accumulated Amortization
          $ (6,524 )
                 
Net Carrying Value
          $ 41,553  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
2016
   
2017
   
2018
   
2019
   
2020
 
$ 3,869     $ 5,685     $ 5,949     $ 5,703     $ 5,703